

**CORRECTION**

# Correction: Digital and precision clinical trials: innovations for testing mental health medications, devices, and psychosocial treatments

Eric Lenze, John Torous and Patricia Arean

© The Author(s), under exclusive licence to American College of Neuropsychopharmacology 2023

*Neuropsychopharmacology* (2024) 49:298; <https://doi.org/10.1038/s41386-023-01746-6>

Correction to: *Neuropsychopharmacology* <https://doi.org/10.1038/s41386-023-01664-7>, published online 07 August 2023


In Figure 1, the text boxes on the left inadvertently repeated the same information. The figure has now been replaced with an updated version. The original article has been corrected.

**1 Decentralized clinical trials**

**Problems**

- Studies are costly and slow
- Failure rate is high
- Study population is often inadequately diverse

**Solution:** fully-remote trial



● Clinical trial site

**Benefits**


- Recruitment rate optimized
- Reduced burden for patients
- Expert site gains experience, continuously increasing quality

**2 Precise measurement**

**Problems**

- Measurement reliability is low
- Leads to study failure
- Barrier to demonstrating mediation, moderation

**Solution:** frequent, valid assessments



**Benefits**

- High measurement reliability
- Sample size requirements reduced
- Potential for precision medicine increased by well-powered mediation

**3 Digital interventions**

**Problems**

- Treatments once tested are not widely available
- Access to treatment is inequitable
- Treatments cannot adapt to the individual patient

**Solution:** digital interventions



**Benefits**

- Treatments scalable to need
- Reach to patients is equitable
- Treatments can auto-adapt to the individual patient, increasing benefits and acceptability